These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 3572025)
21. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration. Yahr MD; Clough CG; Bergmann KJ Lancet; 1982 Sep; 2(8300):709-10. PubMed ID: 6126641 [No Abstract] [Full Text] [Related]
22. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Cannas A; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Costanzo AM; Gualberti G; Melzi G; di Luzio Paparatti U; Antonini A Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834 [TBL] [Abstract][Full Text] [Related]
23. [Pharmacoeconomic aspects of combined treatment of advanced stage of Parkinson's disease]. Rudakova AV; Levin OS Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6. Vyp. 2):96-100. PubMed ID: 28980620 [TBL] [Abstract][Full Text] [Related]
24. Melanin synthesis and the action of L-dopa and 3,4-dihydroxybenzylamine in human melanoma cells. Kable EP; Parsons PG Cancer Chemother Pharmacol; 1989; 23(1):1-7. PubMed ID: 2909284 [TBL] [Abstract][Full Text] [Related]
29. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). Silver DE Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578 [TBL] [Abstract][Full Text] [Related]
30. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells. Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119 [TBL] [Abstract][Full Text] [Related]
31. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy. Colamartino M; Duranti G; Ceci R; Sabatini S; Testa A; Cozzi R Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800 [TBL] [Abstract][Full Text] [Related]
32. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease. Delea TE; Thomas SK; Hagiwara M; Mancione L Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819 [TBL] [Abstract][Full Text] [Related]
34. The effect of central and peripheral dopamine-agonists on ventilation in the mouse. Olson LG; Saunders NA Respir Physiol; 1985 Sep; 61(3):335-45. PubMed ID: 4059691 [TBL] [Abstract][Full Text] [Related]
35. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Nyholm D; Klangemo K; Johansson A Eur J Neurol; 2012 Aug; 19(8):1079-85. PubMed ID: 22360705 [TBL] [Abstract][Full Text] [Related]
36. Alleviation of severe emotional symptoms by carbidopa-levodopa, MSD, in a Parkinson's patient: a personal report. Doe J J Nerv Ment Dis; 1987 Mar; 175(3):185-6. PubMed ID: 3819716 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients. Mizutani Y; Okada Y; Ogawa M; Hasegawa T; Nabeshima T Biol Pharm Bull; 1995 Dec; 18(12):1729-37. PubMed ID: 8787797 [TBL] [Abstract][Full Text] [Related]
38. Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. Braun M; Cawello W; Andreas JO; Boekens H; Horstmann R J Clin Pharmacol; 2009 Sep; 49(9):1047-55. PubMed ID: 19628729 [TBL] [Abstract][Full Text] [Related]
39. Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma. Pierson HF; Meadows GG Cancer Res; 1983 May; 43(5):2047-51. PubMed ID: 6831435 [TBL] [Abstract][Full Text] [Related]
40. The use of L-dopa and carbidopa in metastatic malignant melanoma. Gurney H; Coates A; Kefford R J Invest Dermatol; 1991 Jan; 96(1):85-7. PubMed ID: 1987300 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]